{"product_id":"axsm-marketing-mix","title":"(AXSM) Axsome Therapeutics, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Axsome Therapeutics, Inc. 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategy and shows how its offerings are positioned and marketed; the page includes a real preview\/sample of the analysis so you can assess style and content before buying. Purchase the full version to receive the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAUVELITY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAUVELITY is Axsome Therapeutics, Inc.'s U.S. commercial antidepressant and the core approved CNS product in its portfolio for major depressive disorder. Built from AXS-05 and FDA-approved in 2022, it gives Axsome a branded, revenue-generating base beyond development-stage assets. In the 4P mix, it is a prescription-only, premium branded therapy aimed at psychiatrists and primary care use in MDD.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSUNOSI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSUNOSI is Axsome Therapeutics, Inc.'s second U.S. commercial product and a key part of its marketed CNS portfolio. It treats excessive daytime sleepiness linked to narcolepsy and obstructive sleep apnea. The brand strengthens Axsome's CNS mix beyond AXS-05, expanding recurring U.S. prescription revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAXS-07 Phase III\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAXS-07 is Axsome Therapeutics, Inc.'s oral investigational migraine treatment, aimed at acute migraine relief. Axsome reported two Phase III studies in acute migraine, which signals real late-stage pipeline depth beyond its approved portfolio. The program also fits a high-value need: migraine affects about 1 in 6 U.S. adults and drives major productivity loss.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAXS-12 Phase III\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAXS-12 is Axsome Therapeutics, Inc.'s selective norepinephrine reuptake inhibitor in Phase III for narcolepsy. It targets a sleep-disorder market with an estimated 170,000 to 200,000 U.S. patients, and Phase III data can help expand Axsome Therapeutics, Inc.'s CNS pipeline beyond its current commercial assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNarcolepsy pipeline asset\u003c\/li\u003e\n\u003cli\u003ePhase III development stage\u003c\/li\u003e\n\u003cli\u003eSelective norepinephrine reuptake inhibitor\u003c\/li\u003e\n\u003cli\u003eSupports sleep-disorder diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAXS-14 Phase III\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAXS-14 is Axsome Therapeutics, Inc.’s oral Phase III CNS asset for fibromyalgia, a pain market affecting about 4 million U.S. adults. It broadens Axsome beyond depression and migraine and keeps the company in late-stage central nervous system drug development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral investigational therapy\u003c\/li\u003e\n\u003cli\u003ePhase III fibromyalgia program\u003c\/li\u003e\n\u003cli\u003eLate-stage CNS pain asset\u003c\/li\u003e\n\u003cli\u003eExpands beyond mood and migraine\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAxsome’s Commercial Core and Late-Stage Pipeline Power Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. Product mix is led by AUVELITY and SUNOSI, the only U.S. commercial brands, while AXS-07, AXS-12, and AXS-14 extend the pipeline into migraine, narcolepsy, and fibromyalgia. AUVELITY targets major depressive disorder, a market with about 21 million U.S. adults in 2025, and SUNOSI broadens recurring CNS revenue. Late-stage assets add optionality, with AXS-07 in Phase III after two studies and AXS-12 and AXS-14 also in Phase III.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAUVELITY\u003c\/td\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003eMDD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAXS-07\u003c\/td\u003e\n\u003ctd\u003ePhase III\u003c\/td\u003e\n\u003ctd\u003eMigraine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConcise, company-specific 4P’s analysis of Axsome Therapeutics’ product, pricing, distribution, and promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTurns Axsome Therapeutics’ 4Ps into a quick, clear snapshot that eases marketing analysis and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of industry reports, clinical data, and regulatory filings to speed due diligence and validate Axsome Therapeutics' market and financial claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S.-only focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. keeps its commercial focus inside the United States, where it sells its CNS medicines and builds its sales force around domestic prescribers. With 2 U.S.-marketed products, Axsome is a U.S. specialty pharma company, not a global consumer brand. That domestic setup limits direct exposure to foreign retail markets and puts most growth tied to U.S. demand and reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew York headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc., founded in 2012, uses its New York, New York headquarters as the main operating base. That site anchors corporate and commercial decision making, including strategy, finance, and U.S. market execution. As of its latest reports, Axsome Therapeutics, Inc. remains centered in New York for leadership and control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacy channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. uses specialty pharmacies and specialty distributors to move CNS brands like Auvelity and Sunosi from prescription to patient, while handling access, fulfillment, and reimbursement. In 2024, Axsome reported $495.7 million in net product sales, showing how important channel execution is for branded CNS growth. These networks also help keep prior-authorization and copay steps moving so patients can start therapy faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrescriber access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. sells prescription CNS medicines through healthcare professionals, not direct consumer retail, so prescribers control access and patient uptake. This fits a physician-led distribution model: doctors diagnose, prescribe, and monitor use, while patients are the end users. Axsome has 2 marketed therapies, so access depends on HCP awareness, formulary coverage, and specialty care reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrescription-only, prescriber-led access\u003c\/li\u003e\n\u003cli\u003ePatients are the end users\u003c\/li\u003e\n\u003cli\u003eAccess depends on HCP adoption\u003c\/li\u003e\n\u003cli\u003e2 marketed therapies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. clinical sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. uses U.S. clinical sites to run late-stage trials, where patients are enrolled, monitored, and assessed in person. This physical footprint matters because Phase 2\/3 studies depend on site-based visits for safety checks, endpoint scoring, and clean data capture. It also shortens start-up risk by keeping development close to the main FDA review market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLate-stage work happens at U.S. trial sites.\u003c\/li\u003e\n\u003cli\u003eSites support enrollment and follow-up.\u003c\/li\u003e\n\u003cli\u003eData are collected under FDA-facing standards.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAxsome’s U.S.-Only Specialty Channel Powers Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. keeps Place tightly U.S.-focused: its branded CNS drugs reach patients through prescribers, specialty pharmacies, and specialty distributors, not mass retail. This channel mix supports prior auth and reimbursement steps, which mattered as net product sales reached $495.7 million in 2024. Its New York headquarters anchors U.S. execution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace lever\u003c\/th\u003e\n\u003cth\u003eAxsome Therapeutics, Inc.\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket scope\u003c\/td\u003e\n\u003ctd\u003eU.S. only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel\u003c\/td\u003e\n\u003ctd\u003eSpecialty pharmacy\/distributor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess\u003c\/td\u003e\n\u003ctd\u003ePrescriber-led\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 sales\u003c\/td\u003e\n\u003ctd\u003e$495.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eAxsome Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual, full Marketing Mix analysis of Axsome Therapeutics, Inc. you’ll receive instantly after purchase—no samples or edits, ready to use for strategy or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHCP detailing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. uses HCP detailing to drive physician-focused promotion for its prescription CNS drugs through education and sales calls. The message is aimed at prescribers in psychiatry, sleep medicine, neurology, and primary care, which matches the launch and use settings for these therapies. This approach supports product uptake by giving clinicians disease-state data, dosing guidance, and patient-selection detail at the point of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific congresses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. uses scientific congresses to present clinical data at medical meetings, which supports evidence-based promotion for AXS-05, AXS-07, AXS-12, and AXS-14. This helps build trust with physicians and payers by showing trial results, safety data, and updates from the pipeline and commercial products. It also keeps Axsome Therapeutics, Inc. visible in key CNS and pain forums where treatment decisions are shaped.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeer-reviewed publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy 2025, Axsome Therapeutics had 3 FDA-approved medicines, and its peer-reviewed trial papers help explain the clinical data behind them. Publishing phase 3 results in journals gives clinicians and researchers a citable record, which supports trust in a science-led promotion strategy. That matters because published data can lift awareness faster than sales copy alone, especially in CNS care where evidence drives prescribing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. uses patient education to reach people indirectly through disease-awareness content that explains symptoms and unmet need in depression, migraine, narcolepsy, and fibromyalgia. That matters in large addressable pools: major depression affects about 21 million U.S. adults, migraine about 39 million, and fibromyalgia about 4 million. This education can nudge treatment-seeking before a diagnosis.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDisease awareness drives indirect patient reach\u003c\/li\u003e\n\u003cli\u003eExplains symptoms and unmet need\u003c\/li\u003e\n\u003cli\u003eSupports treatment-seeking across 4 conditions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDuke collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc.'s Duke University collaboration on AXS-05 for smoking cessation works as promotion through third-party validation. A named research partner like Duke adds scientific credibility, which can support prescriber trust and de-risk the story around the program.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThird-party clinical validation\u003c\/li\u003e\n\u003cli\u003eSupports AXS-05 smoking-cessation positioning\u003c\/li\u003e\n\u003cli\u003eStrengthens trust with physicians\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAxsome’s Evidence-Driven Promotion Gains Momentum in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. promotes mainly through HCP detailing, congress data, and peer-reviewed trials, so its message stays tied to clinical evidence. By 2025, the Company had 3 FDA-approved medicines, which gives its sales and medical teams more proof points in psychiatry, neurology, sleep, and pain. Disease-awareness content and the Duke University AXS-05 smoking-cessation tie-up add patient reach and third-party trust.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePromotion lever\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA-approved medicines\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore channels\u003c\/td\u003e\n\u003ctd\u003eHCP detailing, congresses, publications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient awareness\u003c\/td\u003e\n\u003ctd\u003eDepression, migraine, narcolepsy, fibromyalgia\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand drug pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. sells prescription branded drugs, so pricing is set like specialty pharma, not OTC. In 2024, Axsome Therapeutics, Inc. reported about $495.7 million in net product sales, showing access is driven by payer coverage and reimbursement, not shelf-price volume. That usually keeps list prices high, but actual net pricing depends on formulary status, prior auth, and rebates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWAC list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. uses WAC as the starting list price for U.S. branded drugs, before rebates and discounts. For branded drugs, the net price is often 20%-40% below WAC after payer talks and access deals. That gap matters, because gross list price sets the anchor, but net sales drive real revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc.’s pricing is tightly tied to formulary access and insurer reimbursement, so payers often decide the out-of-pocket cost patients actually face. For CNS drugs like Auvelity and Sunosi, prior authorization is common, and that friction can slow starts even when coverage is broad. In 2025, management said access wins were a key driver of prescription growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCopay support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. uses copay support to cut out-of-pocket costs for commercially insured patients, which matters most for branded prescription therapies. This kind of savings program helps reduce first-fill friction and can improve access when list prices are high. In practice, it makes the therapy feel more affordable at the pharmacy counter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLowers patient cash cost\u003c\/li\u003e\n\u003cli\u003eSupports branded drug access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Axsome Therapeutics, Inc., that affordability signal can help speed starts and repeat fills.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAccess contracting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. uses access contracting to protect net price as U.S. payers, PBMs, rebates, discounts, and specialty pharmacy terms push down gross-to-net. That is normal in biopharma, and it helps Axsome keep patient access while managing price realization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRebates reduce net revenue.\u003c\/li\u003e\n\u003cli\u003eSpecialty pharmacy terms shape access.\u003c\/li\u003e\n\u003cli\u003eGross-to-net pressure is managed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAxsome’s Real Pricing Power Depends on Access, Not Sticker Price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAxsome Therapeutics, Inc. prices like a specialty pharma company: list price starts at WAC, but net price is cut by rebates, payer terms, and copay support. In 2024, net product sales were about $495.7 million, so access and reimbursement matter more than sticker price. For branded CNS drugs, net pricing can run 20%-40% below WAC.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net product sales\u003c\/td\u003e\n\u003ctd\u003e$495.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet vs WAC\u003c\/td\u003e\n\u003ctd\u003e20%-40% below WAC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey price driver\u003c\/td\u003e\n\u003ctd\u003eFormulary access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234158027017,"sku":"axsm-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/axsm-marketing-mix.webp?v=1785712296","url":"https:\/\/dcfanalyst.com\/products\/axsm-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}